Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH

By A. Coletta, A. Clark, P. Banarjee, J. Cleland. 2002

140 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A Disintegrin and Metalloproteinase (ADAM) and ADAM with Thrombospondin Motifs (ADAMTS) Family in Vascular Biology and Disease (2019, background): “Experimental studies in animal models have suggested that inhibiting the TNFα pathway could have therapeutic benefits in cardiovascular disease [87, 88]; however, antiTNFα treatment did not show much improvement in patients with late-stage heart failure [89, 90].”
ADAMs family and relatives in cardiovascular physiology and pathology. (2016, background): “TNFα is elevated in heart disease and animal studies have reported beneficial outcomes from suppression of the TNFα pathway [83,84] although patients in late-stage heart failure did not show any improvements from anti-TNFα treatments [85,86].”